Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

  1. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188:740-748. 
  2. Yosipovitch G, de Bruin-Weller M, Wiseman M, et al. Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: results from two phase 3 trials in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol. 2024:llae541.
  3. Krupka-Olek M, Bożek A, Aebisher D, et al. Potential aspects of the use of cytokines in atopic dermatitis. Biomedicines. 2024;12:867.
  4. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71:1218-1233.
  5. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations. Ann Allergy Asthma Immunol. 2024;132:274-312.
  6. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90:e43-e56.

 

Continue the activity for another interactive case.